P—Reference library
Metabolic and GLP-1 peptides
Regulatory status and a summary of what is reported and claimed.
5 of 29 peptides
| Name | Type | Compounding | Categories | Evidence level | Ev. vs. Hype | Momentum | WADA | Reviewed | + |
|---|---|---|---|---|---|---|---|---|---|
| Cagrilintide | Investigational | Trial use only | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Rising | Prohibited | 2026-10-30 | |
| CagriSema Cagrilintide + semaglutide | Investigational | Not allowed (blends excluded) | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Watch | Prohibited | 2026-10-30 | |
| Retatrutide LY3437943 | Investigational | Trial use only | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Rising | Prohibited | 2026-10-30 | |
| Semaglutide Ozempic · Wegovy · Rybelsus | FDA Approved | Approved product (not applicable) | Metabolic / GLP-1 | Human RCTs (approved use) | Evidence Hype | Steady | Not prohibited | 2026-10-30 | |
| Tirzepatide Mounjaro · Zepbound | FDA Approved | Approved product (not applicable) | Metabolic / GLP-1 | Human RCTs (approved use) | Evidence Hype | Rising | Not prohibited | 2026-10-30 |